Tags

Type your tag names separated by a space and hit enter

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
Epidemiol Psychiatr Sci. 2018 08; 27(4):327-335.EP

Abstract

Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) CBD administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1A receptor agonism; (c) CBD may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of CBD still lack significant results in psychiatric disorders. In conclusion, current evidences suggest that CBD has the ability to reduce psychotic, anxiety and withdrawal symptoms by means of several hypothesised pharmacological properties. However, further studies should include larger randomised controlled samples and investigate the impact of CBD on biological measures in order to correlate CBD's clinical effects to potential modifications of neurotransmitters signalling and structural and functional cerebral changes.

Authors+Show Affiliations

Department of Neurosciences and Mental Health,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,University of Milan,Milan,Italy.Department of Neurosciences and Mental Health,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,University of Milan,Milan,Italy.Department of Neurosciences and Mental Health,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,University of Milan,Milan,Italy.Department of Neurosciences and Mental Health,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,University of Milan,Milan,Italy.Department of Pathophysiology and Transplantation,University of Milan,Milan,Italy.Department of Pathophysiology and Transplantation,University of Milan,Milan,Italy.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

29789034

Citation

Mandolini, G M., et al. "Pharmacological Properties of Cannabidiol in the Treatment of Psychiatric Disorders: a Critical Overview." Epidemiology and Psychiatric Sciences, vol. 27, no. 4, 2018, pp. 327-335.
Mandolini GM, Lazzaretti M, Pigoni A, et al. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018;27(4):327-335.
Mandolini, G. M., Lazzaretti, M., Pigoni, A., Oldani, L., Delvecchio, G., & Brambilla, P. (2018). Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiology and Psychiatric Sciences, 27(4), 327-335. https://doi.org/10.1017/S2045796018000239
Mandolini GM, et al. Pharmacological Properties of Cannabidiol in the Treatment of Psychiatric Disorders: a Critical Overview. Epidemiol Psychiatr Sci. 2018;27(4):327-335. PubMed PMID: 29789034.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. AU - Mandolini,G M, AU - Lazzaretti,M, AU - Pigoni,A, AU - Oldani,L, AU - Delvecchio,G, AU - Brambilla,P, Y1 - 2018/05/23/ PY - 2018/5/24/pubmed PY - 2018/11/7/medline PY - 2018/5/24/entrez KW - Antianxiety agents KW - antipsychotics KW - clinical drug studies KW - drugs new KW - psychopharmacology SP - 327 EP - 335 JF - Epidemiology and psychiatric sciences JO - Epidemiol Psychiatr Sci VL - 27 IS - 4 N2 - Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) CBD administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1A receptor agonism; (c) CBD may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of CBD still lack significant results in psychiatric disorders. In conclusion, current evidences suggest that CBD has the ability to reduce psychotic, anxiety and withdrawal symptoms by means of several hypothesised pharmacological properties. However, further studies should include larger randomised controlled samples and investigate the impact of CBD on biological measures in order to correlate CBD's clinical effects to potential modifications of neurotransmitters signalling and structural and functional cerebral changes. SN - 2045-7960 UR - https://www.unboundmedicine.com/medline/citation/29789034/Pharmacological_properties_of_cannabidiol_in_the_treatment_of_psychiatric_disorders:_a_critical_overview_ L2 - https://www.cambridge.org/core/product/identifier/S2045796018000239/type/journal_article DB - PRIME DP - Unbound Medicine ER -